A Boston-area plant that French drugmaker Ipsen had poured tens of millions of dollars into will be included in an auction of assets now that its partner, Inspiration Biopharmaceuticals, has filed for Chapter 11 bankruptcy protection.
Problems that began three years ago with K-V Pharmaceuticals hiding manufacturing lapses from the FDA have escalated into a Chapter 11 bankruptcy filing by the maker of Makena, a drug to prevent premature birth.
After almost three months of deliberations in U.S. Bankruptcy Court in Delaware, a bid has been accepted toward the sale of the North Carolina CRO.
As it settles its differences with the FDA and embarks on finding new ownership, Cetero Research is being pursued by a California biotech that wants almost $250,000 from the troubled CRO, alleging a breach of contract.
This week, a 10-day extension was issued by a Delaware bankruptcy court so that unsecured creditors can submit their own purchase bid to buy Cetero.
Despite filing for Chapter 11 on Monday, Cetero has no plans to cease daily operations or ongoing research.
Two weeks ago, when Repros Therapeutics suspended late stage trials of Proellex after researchers saw signs of spiking liver enzymes in patients, the company said it would have to keep a close eye on
Medical University of South Carolina spin-out Argolyn Bioscience has filed for bankruptcy following unimpressive preclinical results for its pain drug. The company, founded in 2002, was developing
Epix Pharmaceuticals put up a fight, but despite all its efforts to round up fresh working capital the developer says it will now have to wind down its operations and close up shop. At the end of
Facing a jury award of more than $36 million, Roanoke, VA-based Luna Innovations filed for bankruptcy protection today. The company is engaged in developing nanomedicines as well as sensing and